Overview: NGS Canavan Disease Sequencing TestIntroduction: The NGS Canavan Disease Sequencing Test sequences genes to diagnose Canavan disease, causing developmental delays or seizures. Aligned with 2023 NORD guidelines, it uses PCR for high specificity, supporting neurological screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected Canavan disease.
Other Names: Canavan Disease Assay, ASPA Gene Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Canavan disease sequencing began in the 1990s with leukodystrophy research. NGS methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Sequences genes to diagnose Canavan disease, guides treatment, and evaluates patients with developmental delays or seizures.
Test Parameters: 1. Canavan Disease Genes
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of developmental delays, seizures, or Canavan symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document developmental delays, seizures, hypotonia, or family history of Canavan disease. Include current medications, especially anticonvulsants.
Consent: Written consent required, detailing the tests purpose, Canavan disease implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to analyze Canavan disease genes (e.g., ASPA). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for Canavan disease diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations confirm Canavan disease, guiding supportive care or genetic counseling. Negative results may require NAA testing.
Specialist Consultation: Consult a neurologist or geneticist for result interpretation and treatment planning.
Additional Supporting Tests: Urine N-acetylaspartic acid (NAA), brain MRI, or EEG to confirm Canavan disease diagnosis.
Test Limitations: Not all Canavan disease cases are detected; clinical correlation is needed. Sample quality affects sensitivity.
References: NORD Canavan Disease Guidelines, 2023; Journal of Inherited Metabolic Disease, Matalon R, 2022.
